A controversial US-funded hepatitis B vaccine trial involving newborns in Guinea-Bissau has been canceled amid fierce criticism over its ethics and design. The study, which planned to withhold the vaccine from half of the participating infants, sparked accusations of neocolonialism and exploitation of vulnerable populations. The cancellation highlights the complex challenges of conducting medical research in low-income countries, especially when global health recommendations are at odds with local practices and political dynamics.
Ethical Concerns Over Withholding a Proven Vaccine
The trial, funded by the US government and linked to Health Secretary Robert F. Kennedy Jr., aimed to enroll 14,000 newborns in Guinea-Bissau. The study intended to compare health outcomes between infants who received the hepatitis B vaccine at birth and those who did not. While the World Health Organization (WHO) has recommended birth-dose hepatitis B vaccination for over 30 years to prevent early-life infections, Guinea-Bissau currently administers the vaccine only at six weeks of age. Researchers argued this created a unique opportunity to study the vaccine’s broader health impacts before the country introduces birth-dose vaccination in 2028.
However, critics, including the WHO representative in Guinea-Bissau, condemned the trial for withholding an already proven and internationally recommended vaccine from half of the infants. This raised serious ethical questions, given the high prevalence of hepatitis B in Guinea-Bissau—nearly 20% of the population is infected—and the increased risk of chronic liver disease and cancer from early infection. Opponents argued that denying half of the babies the vaccine exposed them to unnecessary risk, a practice unlikely to be accepted in wealthier countries.
Neocolonialism and Power Imbalances in Global Health Research
Beyond the immediate ethical debate, the trial reignited longstanding concerns about neocolonial dynamics in global health research. Critics questioned why such a study was proposed in one of the world’s poorest countries rather than in Denmark, where the lead researchers are based. The asymmetry in decision-making power, where high-income countries design and fund studies that involve vulnerable populations in low-income settings, often leads to accusations of exploitation and disregard for local autonomy.
Global health experts warned that trials like this risk perpetuating a pattern where African populations bear risks that would be unacceptable in wealthier nations. The fact that the trial was linked to a US health official known for vaccine skepticism further fueled suspicions about the motivations behind the study. Some feared the research might be used to support policy changes that roll back birth-dose hepatitis B vaccination in the US, although no direct evidence supports this claim.
Local Backlash and Government Intervention
The Guinea-Bissau government reacted strongly against the proposed trial. In January, it banned hepatitis B vaccine trials involving children and requested an independent review by the Africa Centres for Disease Control and Prevention. The Health Minister expressed outrage upon learning through media reports that the study might proceed despite the ban. The government emphasized that no authorization had been granted for the trial to move forward.
In a dramatic escalation, Guinea-Bissau’s Judicial Police raided the Bandim Health Project research center in the capital, Bissau, seizing a batch of hepatitis B vaccines. While authorities did not clarify whether the seizure was directly related to the trial, it underscored the government’s determination to halt the study. The Bandim Health Project has been a key research institution in Guinea-Bissau since 1978, but this controversy has cast a shadow over its work and raised questions about oversight and transparency.
The Complex Landscape of Vaccine Policy and Research
The hepatitis B vaccine is a critical tool in preventing liver disease and cancer worldwide. The WHO recommends administering the first dose within 24 hours of birth to maximize effectiveness, especially in high-prevalence countries. Guinea-Bissau’s current practice of vaccinating at six weeks reduces the vaccine’s protective benefit against early infection.
The US-funded trial sought to explore whether the vaccine has broader health effects beyond preventing hepatitis B infection, a subject of earlier studies that yielded conflicting results. Some prior research by Danish scientists suggested possible links between the vaccine and increased infant mortality, though subsequent studies found no such effect. The controversy highlights the difficulties in interpreting complex vaccine data and the importance of rigorous, ethically sound research.
At the same time, the political context in the US has influenced vaccine policy debates. Under the Trump administration and Health Secretary Kennedy, there were attempts to alter longstanding vaccine recommendations, including for hepatitis B. These efforts were ultimately blocked by federal courts, but the association between the trial and US vaccine policy skepticism has raised suspicions about the study’s true intent.
Looking Ahead: Balancing Research, Ethics, and Global Health Equity
The cancellation of the Guinea-Bissau hepatitis B vaccine trial serves as a cautionary tale about the ethical pitfalls of conducting clinical research in vulnerable populations. It underscores the necessity of transparent collaboration with local governments, adherence to international ethical standards, and sensitivity to historical power imbalances.
As Guinea-Bissau moves toward introducing birth-dose hepatitis B vaccination in the near future, the focus should shift to strengthening immunization programs and ensuring equitable access to lifesaving vaccines. For global health researchers and funders, this episode is a reminder that scientific inquiry must never come at the expense of the rights and well-being of those it aims to serve.
Recommended reading
For more context, see related Peack News coverage and explainers linked below.